Palatinose™ (Isomaltulose)

Evidence Level
Strong
3 Clinical Trials
4 Documented Benefits
4/5 Evidence Score

Palatinose™ is Beneo's branded enzymatically rearranged sucrose — an alpha-1,6-linked disaccharide of glucose and fructose, commonly named isomaltulose. The alpha-1,6 bond is hydrolyzed by intestinal isomaltase several times more slowly than the alpha-1,2 bond of sucrose, producing a low-glycemic carbohydrate that is fully digested and absorbed but releases glucose into circulation gradually. In randomized human trials, isomaltulose produces a flatter postprandial glucose and insulin curve than sucrose or maltodextrin, sustains blood glucose during prolonged exercise, supports higher fat oxidation during cycling, and is being explored as a carbohydrate of choice for people with prediabetes and metabolic syndrome.

Studied Dose 25–75 g per dose in acute glycemic and exercise trials, typically replacing sucrose or maltodextrin gram-for-gram; pre-exercise doses of 50–75 g in cycling performance studies.
Active Compound Isomaltulose — 6-O-α-D-glucopyranosyl-D-fructose (alpha-1,6-linked glucose-fructose disaccharide), branded as Palatinose™ by Beneo

Benefits

Low-glycemic carbohydrate energy

Isomaltulose produces a notably lower and flatter postprandial blood glucose and insulin response than sucrose or maltodextrin in healthy adults, providing slow-release carbohydrate energy that can be useful in mixed-nutrient meals, sports nutrition, and glycemic-management contexts.

Sustained exercise fueling

When taken before prolonged cycling, isomaltulose helps maintain blood glucose during exercise and supports cycling performance versus rapid carbohydrates, while producing higher rates of fat oxidation across the exercise bout.

Lower postprandial glucose variability

Isomaltulose-based foods and drinks reduce postprandial glucose excursions and variability versus matched higher-glycemic carbohydrates in healthy and prediabetic adults, helping support steadier post-meal energy.

Metabolic-syndrome-friendly carbohydrate

Isomaltulose produces favorable acute metabolic effects on glucose, insulin, and substrate use compared with rapidly absorbed sugars — properties that make it attractive in formulated nutrition for people with metabolic syndrome or impaired glucose tolerance.

Mechanism of action

1

Slow intestinal hydrolysis

The alpha-1,6 glycosidic bond between glucose and fructose in isomaltulose is hydrolyzed by intestinal isomaltase several times more slowly than the alpha-1,2 bond in sucrose, slowing glucose release into the bloodstream while delivering the same caloric load.

2

Gradual insulin demand

Because absorption is slower, the pancreatic insulin response is lower and more sustained, avoiding the sharp insulin spike characteristic of rapidly absorbed carbohydrates and supporting steadier glycemic regulation.

3

Higher fat oxidation during exercise

By keeping blood glucose stable rather than producing large spikes and dips, isomaltulose preserves a higher contribution of fat to total energy expenditure during prolonged moderate-intensity exercise, as observed in controlled cycling trials.

Clinical trials

1
Palatinose for Substrate Use and Cycling Performance

Randomized, double-blind, controlled trial in trained cyclists comparing Palatinose (isomaltulose) and maltodextrin ingestion before a cycling performance test, measuring substrate utilization, blood glucose stability, and cycling performance.

Trained cyclists.

Isomaltulose produced a more stable blood glucose profile and higher fat oxidation during exercise, with improved cycling performance versus maltodextrin. Supports the use of isomaltulose as a sustained-energy carbohydrate for endurance fueling.

2
Isomaltulose in a Low-GI Diet for Asian Adults

Study evaluating a low-glycemic-index diet incorporating isomaltulose versus a higher-GI comparator in Asian adults, with continuous glucose monitoring and indirect calorimetry to assess glycemic response, variability, and fat oxidation.

Asian adults.

A diet incorporating isomaltulose produced lower glycemic response and lower glycemic variability versus the higher-GI diet, and supported higher fat oxidation. Supports the low-glycemic-carbohydrate and metabolic-flexibility claims for isomaltulose.

3
Isomaltulose vs Rapid Carbohydrate in T2D

Randomized trial comparing slowly absorbed (isomaltulose) versus rapidly absorbed carbohydrates on postprandial glucose metabolism in adults with type 2 diabetes.

Adults with type 2 diabetes.

Isomaltulose produced lower postprandial glucose excursions and a more favorable glucose-handling profile than the rapidly absorbed comparator in this T2D population. Supports the metabolic-syndrome-friendly and lower-glucose-variability claims.

Side effects and drug interactions

Common Potential side effects

Mild gastrointestinal discomfort, bloating, or gas at very large doses.
Provides ~4 kcal/g — calories should be counted as part of total intake.
Not suitable for people with hereditary fructose intolerance.
May increase blood glucose in unmonitored diabetes despite low glycemic index.

Important Drug interactions

Insulin and sulfonylureas — like any carbohydrate, isomaltulose raises glucose; coordinate timing with medication.
Acarbose and alpha-glucosidase inhibitors — these drugs target the same enzymes that hydrolyze isomaltulose; further slowed absorption possible.
GLP-1 receptor agonists (semaglutide, liraglutide) — combined gastric slowing may amplify post-meal effects; monitor.
SGLT2 inhibitors — additive glucose-lowering possible in T2D patients; monitor.

Frequently asked questions about Palatinose™ (Isomaltulose)

What is the recommended dosage of Palatinose™ (Isomaltulose)?

The clinically studied dose for Palatinose™ (Isomaltulose) is 25–75 g per dose in acute glycemic and exercise trials, typically replacing sucrose or maltodextrin gram-for-gram; pre-exercise doses of 50–75 g in cycling performance studies.. Always follow product labeling and consult a healthcare provider for personalized dosing recommendations.

What is Palatinose™ (Isomaltulose) used for?

Palatinose™ (Isomaltulose) is studied for low-glycemic carbohydrate energy, sustained exercise fueling, lower postprandial glucose variability. Isomaltulose produces a notably lower and flatter postprandial blood glucose and insulin response than sucrose or maltodextrin in healthy adults, providing slow-release carbohydrate energy that can be useful in mixed-nutrient meals, sports nutrition,…

Are there side effects from taking Palatinose™ (Isomaltulose)?

Reported potential side effects may include: Mild gastrointestinal discomfort, bloating, or gas at very large doses. Provides ~4 kcal/g — calories should be counted as part of total intake. Always consult a healthcare provider before starting any new supplement, especially if you have underlying conditions or take medications.

Does Palatinose™ (Isomaltulose) interact with medications?

Known drug interactions may include: Insulin and sulfonylureas — like any carbohydrate, isomaltulose raises glucose; coordinate timing with medication. Acarbose and alpha-glucosidase inhibitors — these drugs target the same enzymes that hydrolyze isomaltulose; further slowed absorption possible. Consult a pharmacist or healthcare provider if you take prescription medications.

Is Palatinose™ (Isomaltulose) good for metabolic health?

Yes, Palatinose™ (Isomaltulose) is researched for Metabolic Health support. Isomaltulose produces favorable acute metabolic effects on glucose, insulin, and substrate use compared with rapidly absorbed sugars — properties that make it attractive in formulated nutrition for people with metabolic syndrome or impaired glucose tolerance.

References(4 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. König D, Zdzieblik D, Holz A, Theis S, Gollhofer A. Substrate Utilization and Cycling Performance Following Palatinose™ Ingestion: A Randomized, Double-Blind, Controlled Trial. Nutrients. 2016;8(7):390. doi: 10.3390/nu8070390.PubMedUsed to support: Randomized double-blind trial in trained cyclists; pre-exercise Palatinose (isomaltulose) produced a more stable blood glucose profile and higher fat oxidation during exercise versus maltodextrin, with improved cycling performance. Backs the sustained-energy and exercise-fueling claims.
  2. Henry CJ, Kaur B, Quek RYC, Camps SG. A Low Glycaemic Index Diet Incorporating Isomaltulose Is Associated with Lower Glycaemic Response and Variability, and Promotes Fat Oxidation in Asians. Nutrients. 2017;9(5):473. doi: 10.3390/nu9050473.PubMedUsed to support: Diet study in Asian adults; a low-glycemic-index diet incorporating isomaltulose produced lower glycemic response and lower glycemic variability than the higher-GI comparator and supported higher fat oxidation. Backs the low-glycemic and metabolic-flexibility claims.
  3. Holub I, Gostner A, Theis S, Nosek L, Kudlich T, Melcher R, Scheppach W. Novel findings on the metabolic effects of the low glycaemic carbohydrate isomaltulose (Palatinose). Br J Nutr. 2010;103(12):1730-7. doi: 10.1017/S0007114509993874.PubMedUsed to support: Foundational metabolic-effects paper on isomaltulose (Palatinose) demonstrating its low-glycemic and low-insulinemic response profile and slowly digestible disaccharide characteristics relevant to functional food formulation. Backs the low-glycemic carbohydrate identity claim.
  4. Ang M, Linn T. Comparison of the effects of slowly and rapidly absorbed carbohydrates on postprandial glucose metabolism in type 2 diabetes mellitus patients: a randomized trial. Am J Clin Nutr. 2014;100(4):1059-68. doi: 10.3945/ajcn.113.076638.PubMedUsed to support: Randomized trial in adults with type 2 diabetes; slowly absorbed isomaltulose produced lower postprandial glucose excursions than rapidly absorbed carbohydrate. Backs the metabolic-syndrome-friendly and lower-variability claims for isomaltulose in glucose-impaired populations.